Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates
Anti-Her2 Antibody-Drug Conjugates in:
September 2016 R&D and Business Tracker for Antibody-Drug Conjugates
This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates.
Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 from AstraZeneca.
The September 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:
R&D and Technology Tracker
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
September 2016 R&D and Business Tracker for Antibody-Drug Conjugates
This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates.
Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 from AstraZeneca.
The September 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
- Manufacturing news
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
- Scientific Publication Tracker
- Featured ADC Profile: MEDI4276
- Featured Company Profile: NBE Therapeutics
- Featured Target Pipeline: Anti-Her2 Antibody-Drug Conjugates
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
